Unlock breakthrough rare disease market insights fast

Access on-demand primary market research reports tailored to your business questions and delivered in as little as 15 days.

Get fresh primary market research-driven insights and answers to your most pressing business questions in 15 days or less

how it works
REPORT STORE

Unlock breakthrough market insights for any disease fast

Get fresh primary market research-driven insights and answers to your most pressing business questions in 15 days or less

Get fresh primary market research-driven insights and answers to your most pressing business questions in 15 days or less

how it works
disease coverage

SHARE YOUR COLORS

Rare Disease Day

February 29, 2024

Follow us on social to find more ways to get involved or visit the Rare Disease Day organization page to donate today.

DONATE

OUR LIFE SCIENCES
MARKET RESEARCH SOLUTIONS

On-demand reports grounded in primary market research

See what our clients are saying

We specialize in niche markets, specifically rare diseases and subpopulations of common diseases.

Explore Diseases we cover

We specialize in niche markets, specifically rare diseases and subpopulations of common diseases.

SEE ALL SYNDICATED REPORTS

OUR DISEASE EXPERTISE

Pharmaceutical R&D is increasingly focused on niche markets such as rare diseases and subpopulations within common diseases. REACH is at the forefront of this exciting shift, specializing in delivering actionable market insights for these specific segments. Having conducted syndicated and custom market research for 192 rare diseases and subpopulations of common conditions, we are well-equipped to help life sciences professionals make strategic product development decisions in these dynamic markets.

EXPLORE OUR SYNDICATED REPORTS
search by disease or therapy area

OUR RESEARCH MODEL

Our senior pharmaceutical market researchers provide timely customizable market insights with a hands-on approach and uncompromising quality.

ON-DEMAND

Fresh market research is conducted upon request for any disease

FAST

New research and insights delivered in 15 days or less

PMR-DRIVEN

Insights informed by qualitative interviews and/or quantitative surveys

SENIOR TEAM

Experienced team members (10+ years in pharma market research) lead the research

CUSTOMIZABLE

Customizable research includes your questions and topics of interest

Meet our team

HOW IT WORKS

GET AN INSTANT QUOTE

HOW IT WORKS

GET STARTED
GET STARTED

WHAT OUR CLIENTS ARE SAYING

It was great to see you at your market access pulse survey readout on Wednesday! The team’s feedback has been consistently very positive with the product quality, Melissa’s expertise, and the process getting the research completed on time. I’m so glad that [name] has you as an obvious go-to-choice for ad hoc requests for [our product].

Sr. Manager, Commercial Analytics

For us, MarketVue® is very valuable to get fast reports and at the right level of detail. We were originally supposed to develop disease strategies but then we had a reorganization and resources were constrained. REACH is a great help to us.

Konstanze Binder

Principal, Global Asset Maximization · LEO Pharma

I need something beyond what I can do for myself with Google and without paying an extraordinary amount of money… MarketVue® goes even further — it’s not your typical syndicated report. It was very collaborative. REACH operates with the best aspects of primary research but then benefits like speed of syndicated reports.

Tony Russell

Director, Commercial Development · Pfizer

With MarketVue® reports, you can get 80-90% of output for 10% of the cost [of custom consulting] — this is great, especially for small clients like us whose budgets are tight, and we don’t have a ton of FTEs. I’m a team of 1. I can’t blow my whole budget on a single question.

Joe Pirrello

Executive Director, Business Development · Astria Therapeutics

Regarding the [rare disease] development program related to our project before the break, I don’t recall if I ever relayed the message – folks were very complimentary of the supportive market research, so THANK YOU very much for a very successful and timely engagement. Let’s stay in touch over the coming weeks on any imminent projects that may materialize on our end.

Director, New Product Commercialization

Before even getting to the MarketVue® product, the process is a huge plus for them. The fact that we can get a tailored report with essentially a proprietary set of questions at that price range with that level of engagement with the team is hugely valuable and gives us a lot of trust with what we receive. MarketVue® is really high quality in general and comparable to much more expensive reports where you get a 100-page report — in terms of value for the amount we use it, it is comparable to much, much more expensive research… They’re really good at highlighting what is most relevant.

Julia Chornak

Senior Manager, Market Insights · Chinook Therapeutics

BTW – I wanted to tell you that the chatter with the [rapid insights] work you just delivered within our NPC team is that you killed it. So, I anticipate you will be our go to for much more work like this in the future.

Director, Pipeline/New Product Commercialization

REACH reports give you the ability to tailor the research a little bit more. I work in rare disease where [syndicated reports] just don’t exist and if they do, they’re not built out. For folks like myself, there is limited ability to use those off-the-shelf reports since they’re focused on mass market. I value the REACH team’s ability and willingness to answer follow up questions, dive in around specific topics, push back on the report, and think critically with us around the implications of the findings… I eventually asked them to synthesize all of our email back/forth into a separate report because I thought it was so useful and thoughtful.

Joe Pirrello

Executive Director, Business Development · Astria Therapeutics

What pushed me over the edge was that they have a nice way of presenting the findings in the end. Sometimes you get a wall of text. Their output was very clean and useful for putting into our slides. I’ve worked with a lot of vendors, and it can be pretty hit or miss. Some vendors can be good at executing, but REACH can be a thought partner. They can take what we’re saying and riff off of us, then come up with additional ideas and put them in front of us.

Kathleen Davenport

Senior Director, New Product Planning · Surface Oncology

Want to know more?

REACH out to our experts or subscribe to our complementary newsletter on rare and niche disease drug development strategy.

CONTACT US
SUBSCRIBE NOW